Streetbeat News

Analyst Ratings

MYNZ

HC Wainwright & Co. analyst Yi Chen reiterates a Buy rating on Mainz Biomed (NASDAQ:MYNZ) and maintains a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 2:38 pm

ESPR

HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintains a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 2:35 pm

PLTR

Bear Cave has published a short report titled 'Problems At Palantir Technologies', raising concerns about the company's business practices and growth prospects.

Portfolio Pulse from Happy Mohamed

June 01, 2023 | 2:33 pm

CLSD

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

June 01, 2023 | 2:22 pm

ICCM

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

June 01, 2023 | 2:20 pm

HQY

Barrington Research analyst Alexander Paris has reiterated an Outperform rating on HealthEquity (NASDAQ:HQY) and maintained an $80 price target.

Portfolio Pulse from richadhand@benzinga.com

June 01, 2023 | 2:19 pm

ALYA

Barrington Research analyst Vincent Colicchio has reiterated an Outperform rating on Alithya Group (NASDAQ:ALYA) and maintained a $3.5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 01, 2023 | 2:18 pm

AVTA

Barrington Research analyst Alexander Paris reiterated an Outperform rating on Avantax (NASDAQ:AVTA) and maintained a $32.5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 01, 2023 | 2:17 pm

DTIL

HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (NASDAQ:DTIL) and maintained a $17 price target.

Portfolio Pulse from richadhand@benzinga.com

June 01, 2023 | 2:16 pm

AYX

Alteryx shares are trading higher after Bank of America Securities upgraded the stock from Neutral to Buy and raised its price target from $60 to $70.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 2:08 pm